{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:58:42Z","timestamp":1772078322946,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,8,3]],"date-time":"2010-08-03T00:00:00Z","timestamp":1280793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1471-2105-11-409","type":"journal-article","created":{"date-parts":[[2010,8,3]],"date-time":"2010-08-03T19:02:59Z","timestamp":1280862179000},"source":"Crossref","is-referenced-by-count":13,"title":["Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape"],"prefix":"10.1186","volume":"11","author":[{"given":"Kristof","family":"Theys","sequence":"first","affiliation":[]},{"given":"Koen","family":"Deforche","sequence":"additional","affiliation":[]},{"given":"Gertjan","family":"Beheydt","sequence":"additional","affiliation":[]},{"given":"Yves","family":"Moreau","sequence":"additional","affiliation":[]},{"given":"Kristel","family":"van Laethem","sequence":"additional","affiliation":[]},{"given":"Philippe","family":"Lemey","sequence":"additional","affiliation":[]},{"given":"Ricardo J","family":"Camacho","sequence":"additional","affiliation":[]},{"given":"Soo-Yon","family":"Rhee","sequence":"additional","affiliation":[]},{"given":"Robert W","family":"Shafer","sequence":"additional","affiliation":[]},{"given":"Eric","family":"Van Wijngaerden","sequence":"additional","affiliation":[]},{"given":"Anne-Mieke","family":"Vandamme","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2010,8,3]]},"reference":[{"key":"3866_CR1","first-page":"243","volume-title":"Antiviral Therapy","author":"AM Vandamme","year":"2001","unstructured":"Vandamme AM, De Clercq E: Antiviral Therapy. Volume chap 12. ASM Press, Washington, US; 2001:243\u2013277."},{"key":"3866_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nrg1246","volume":"5","author":"A Rambaut","year":"2004","unstructured":"Rambaut A, Posada D, Crandall KA, Holmes EC: The causes and consequences of HIV evolution. Nat Rev Genet 2004, 5: 52\u201361. 10.1038\/nrg1246","journal-title":"Nat Rev Genet"},{"issue":"6","key":"3866_CR3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/135965350400900619","volume":"9","author":"AM Vandamme","year":"2004","unstructured":"Vandamme AM, Sonnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, BrunVezinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr H, Faudon J, Gatti G, Gerstoft J, Hall W, Hatzakis A, Hellmann N, Horban A, Lundgren J, Kempf D, Miller M, Miller V, Myers T, Nielsen C, Opravil M, Palmisano L, Perno C, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit J, Schuurman R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R, Perrin L: Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004, 9(6):829\u201348.","journal-title":"Antivir Ther"},{"issue":"5","key":"3866_CR4","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1128\/AAC.49.5.1671-1678.2005","volume":"49","author":"MA Wainberg","year":"2005","unstructured":"Wainberg MA, Brenner BG, Turner D: Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2005, 49(5):1671\u20131678. 10.1128\/AAC.49.5.1671-1678.2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3866_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jama.283.2.229","volume":"283","author":"DV Havlir","year":"2000","unstructured":"Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP, Richman DD: Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing Regimens. JAMA 2000, 283(2):229\u2013234. 10.1001\/jama.283.2.229","journal-title":"JAMA"},{"issue":"9","key":"3866_CR6","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1097\/00002030-200006160-00017","volume":"14","author":"M Maguire","year":"2000","unstructured":"Maguire M, Gartland M, Moore S, Hill A, Tisdale M, Harrigan R, Kleim JP: Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine\/lamivudine\/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS 2000, 14(9):1195\u20131201. 10.1097\/00002030-200006160-00017","journal-title":"AIDS"},{"issue":"2","key":"3866_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/00002030-200401230-00012","volume":"18","author":"M Violin","year":"2004","unstructured":"Violin M, Cozzi-Lepri A, Velleca R, Vincenti A, D'Elia S, Chiodo F, Ghinelli F, Bertoli A, d'Arminio Monforte A, Perno CF, Moroni M, Balotta C: Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 2004, 18(2):227\u2013235. 10.1097\/00002030-200401230-00012","journal-title":"AIDS"},{"issue":"3","key":"3866_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1386-6532(03)00115-X","volume":"29","author":"R Kantor","year":"2004","unstructured":"Kantor R, Katzenstein D: Drug resistance in non- subtype B HIV-1. J Clin Virol 2004, 29(3):152\u2013159. 10.1016\/S1386-6532(03)00115-X","journal-title":"J Clin Virol"},{"key":"3866_CR9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/135965350601100512","volume":"11","author":"AB Abecasis","year":"2006","unstructured":"Abecasis AB, Deforche K, Bacheler LT, McKenna P, Carvalho AP, Gomes P, Vandamme AM, Camacho RJ: Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir Ther (Lond) 2006, 11: 581\u2013589.","journal-title":"Antivir Ther (Lond)"},{"issue":"3","key":"3866_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/01.qai.0000209899.05126.e4","volume":"41","author":"DA van de Vijver","year":"2006","unstructured":"van de Vijver DA, Wensing AMJ, Angarano G, Asj\u00f6 B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, Luca AD, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, K\u00fccherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, de Coul ELMO, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-St\u00f6ckl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Laethem KV, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CAB: The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006, 41(3):352\u201360. 10.1097\/01.qai.0000209899.05126.e4","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"3866_CR11","doi-asserted-by":"publisher","first-page":"813","DOI":"10.7326\/0003-4819-131-11-199912070-00003","volume":"131","author":"AR Zolopa","year":"1999","unstructured":"Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC, Efron B: HIV-1 Genotypic Resistance Patterns Predict Response to Saquinavir-Ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed. Ann Intern Med 1999, 131(11):813\u2013821.","journal-title":"Ann Intern Med"},{"issue":"5","key":"3866_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/00002030-200103300-00009","volume":"15","author":"CS Alexander","year":"2001","unstructured":"Alexander CS, Dong W, Chan K, Jahnke N, O'Shaughnessy MV, Mo T, Piaseczny MA, Montaner JSG, Harrigan PR: HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort. AIDS 2001, 15(5):601\u20137. 10.1097\/00002030-200103300-00009","journal-title":"AIDS"},{"issue":"8","key":"3866_CR13","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1086\/323604","volume":"184","author":"CF Perno","year":"2001","unstructured":"Perno CF, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, Facchi G, Pezzotti P, Cadeo G, Tositti G, Pasquinucci S, Pauluzzi S, Scalzini A, Salassa B, Vincenti A, Phillips AN, Dianzani F, Appice A, Angarano G, Monno L, Ippolito G, Moroni M, d'Arminio Monforte A, the Italian Cohort Naive Antiretroviral (ICONA) Study Group: Secondary Mutations in the Protease Region of Human Immunodeficiency Virus and Virologic Failure in Drug-Naive Patients Treated with Protease Inhibitor Based Therapy. J Infec Dis 2001, 184(8):983\u201391. 10.1086\/323604","journal-title":"J Infec Dis"},{"issue":"3","key":"3866_CR14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1128\/AAC.45.3.893-900.2001","volume":"45","author":"J Servais","year":"2001","unstructured":"Servais J, Lambert C, Fontaine E, Plesseria JM, Robert I, Arendt V, Staub T, Schneider F, Hemmer R, Burtonboy G, Schmit JC: Variant Human Immunodeficiency Virus Type 1 Proteases and Response to Combination Therapy Including a Protease Inhibitor. Antimicrob Agents Chemother 2001, 45(3):893\u2013900. 10.1128\/AAC.45.3.893-900.2001","journal-title":"Antimicrob Agents Chemother"},{"key":"3866_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/bioinformatics\/btm540","volume":"24","author":"K Deforche","year":"2008","unstructured":"Deforche K, Camacho R, Van Laethem K, Lemey P, Rambaut A, Moreau Y, Vandamme AM: Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment. Bioinformatics 2008, 24: 34\u201341. 10.1093\/bioinformatics\/btm540","journal-title":"Bioinformatics"},{"issue":"4","key":"3866_CR16","first-page":"125","volume":"14","author":"VA Johnson","year":"2006","unstructured":"Johnson VA, Brun-V\u00e9nizet F, Bonaventura C, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD: Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med 2006, 14(4):125\u201330.","journal-title":"Top HIV Med"},{"issue":"5","key":"3866_CR17","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1128\/AAC.49.5.2015-2025.2005","volume":"49","author":"V Svicher","year":"2005","unstructured":"Svicher V, Ceccherini-Silberstein F, Erba Fu, Santoro M, Gori C, Bellocchi MC, Giannella S, Trotta MP, Monforte Ad, Antinori A, Perno CF: Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors. Antimicrob Agents Chemother 2005, 49(5):2015\u20132025. 10.1128\/AAC.49.5.2015-2025.2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"3866_CR18","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.1128\/JVI.77.8.4836-4847.2003","volume":"77","author":"TD Wu","year":"2003","unstructured":"Wu TD, Shiffer CA, Gonzales MJ, Taylor J, Kantor R, Chou S, Israelski D, Zolopa AR, Fessel WJ, Shafer RW: Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 2003, 77(8):4836\u20134847. 10.1128\/JVI.77.8.4836-4847.2003","journal-title":"J Virol"},{"issue":"21","key":"3866_CR19","doi-asserted-by":"publisher","first-page":"10794","DOI":"10.1128\/JVI.00712-06","volume":"80","author":"JD Baxter","year":"2006","unstructured":"Baxter JD, Schapiro JM, Boucher CAB, Kohlbrenner VM, Hall DB, Scherer JR, Mayers DL: Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006, 80(21):10794\u201310801. 10.1128\/JVI.00712-06","journal-title":"J Virol"},{"issue":"16","key":"3866_CR20","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1097\/01.aids.0000188422.95162.b7","volume":"19","author":"AB Abecasis","year":"2005","unstructured":"Abecasis AB, Deforche K, Snoeck J, Bacheler LT, Kenna PM, Carvalho AP, Gomes P, Camacho RJ, Vandamme AM: Protease mutation M89I\/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 2005, 19(16):1799\u20131806. 10.1097\/01.aids.0000188422.95162.b7","journal-title":"AIDS"},{"issue":"2","key":"3866_CR21","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1177\/135965350200700206","volume":"7","author":"K Van Laethem","year":"2002","unstructured":"Van Laethem K, De Luca A, Antinori A, Cingolani A, Perno CF, Vandamme AM: A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1 infected patients. Antivir Ther 2002, 7(2):1359\u20136535.","journal-title":"Antivir Ther"},{"key":"3866_CR22","volume-title":"Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents","author":"Department of Health and Human Services","year":"2006","unstructured":"Department of Health and Human Services: Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2006."},{"key":"3866_CR23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/135965350801300316","volume":"13","author":"K Deforche","year":"2008","unstructured":"Deforche K, Cozzi-Lepri A, Theys K, Clotet B, Camacho RJ, Kjaer J, Van Laethem K, Phillips A, Moreau Y, Lundgren JD, Vandamme AM: Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. Antivir Ther (Lond) 2008, 13: 399\u2013407.","journal-title":"Antivir Ther (Lond)"},{"issue":"5","key":"3866_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/095632020401500504","volume":"15","author":"D Turner","year":"2004","unstructured":"Turner D, Roldan A, Brenner B, Moisi D, Routy JP, Wainberg MA: Variability in the PR and RT genes of HIV-1 isolated from recently infected subjects. Antivir Chem Chemother 2004, 15(5):255\u2013259.","journal-title":"Antivir Chem Chemother"},{"key":"3866_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/nar\/29.1.296","volume":"29","author":"R Kantor","year":"2001","unstructured":"Kantor R, Machekano R, Gonzales MJ, Dupnik K, Schapiro JM, Shafer RW: Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language and sequence analysis programs. Nucleic Acids Res 2001, 29: 296\u20139. 10.1093\/nar\/29.1.296","journal-title":"Nucleic Acids Res"},{"issue":"19","key":"3866_CR26","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1093\/bioinformatics\/bti607","volume":"21","author":"T de Oliveira","year":"2005","unstructured":"de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, Snoeck J, van Rensburg EJ, Wensing AMJ, van de Vijver DA, Boucher CA, Camacho R, Vandamme AM: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005, 21(19):3797\u2013800. 10.1093\/bioinformatics\/bti607","journal-title":"Bioinformatics"},{"issue":"24","key":"3866_CR27","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1093\/bioinformatics\/btl508","volume":"22","author":"K Deforche","year":"2006","unstructured":"Deforche K, Silander T, Camacho R, Grossman Z, Soares MA, Van Laethem K, Kantor R, Moreau Y, Vandamme AM, non B Workgroup: Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance. Bioinformatics 2006, 22(24):2975\u20139. 10.1093\/bioinformatics\/btl508","journal-title":"Bioinformatics"},{"key":"3866_CR28","volume-title":"R: A language and environment for statistical computing","author":"R Development Core Team","year":"2004","unstructured":"R Development Core Team: R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2004. [ISBN 3-900051- 00-3]"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2105-11-409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2105-11-409\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2105-11-409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:39:27Z","timestamp":1711672767000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/1471-2105-11-409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,3]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["3866"],"URL":"https:\/\/doi.org\/10.1186\/1471-2105-11-409","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,3]]},"article-number":"409"}}